M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.
Berlin, September 10, 2018 – The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today decided to increase the company’s share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 10,2018 by partially utilizing the authorized capital 2018. The Supervisory Board has approved the Management Board’s decision.
The share capital of the company is to be increased – by the partial utilization of the authorized capital 2018 of currently € 16,500,000.00 – by issuing up to 1,650,000 bearer shares to a total share capital of up to € 18,150,000.00. The new shares are to be eligible for dividends as of January 1,2018 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company’s shares. The placement price will not be significantly lower than the market price.
The final placement volume and the placement share price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and will be announced in a separate ad hoc announcement.
M1 Kliniken AG intends to use the proceeds from the capital increase to finance its expansion into new medical indications as well as the opening of additional M1-locations in Germany and abroad.
M1 Kliniken AG
The Board of Directors
The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to “qualified investors” within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.